摘要 |
<p>It is intended to provide a novel heterocyclic compound having an HCV entry inhibition activity and a medicinal application thereof. The invention relates to the use of the heterocyclic compound represented by the general formula [1]: [wherein Q<SUB>1</SUB> represents N= or the like, Q<SUB>2</SUB> represents N or the like, Q<SUB>3</SUB> represents N= or the like, Q<SUB>4</SUB> represents N or the like, Q<SUB>5</SUB> represents N or the like, R<SUP>1</SUP> represents a hydrogen atom or the like, R<SUP>2</SUP> represents a hydrogen atom or the like, the ring A represents a monocyclic aryl group which may have a substituent or the like and the ring B represents a monocyclic aryl group which may have a substituent or the like], a pharmaceutically acceptable salt thereof for the production of a therapeutic agent for hepatitis C and so on.</p> |
申请人 |
JAPAN TOBACCO INC.;UENO, HIROSHI;SHIMADA, TAKASHI;AOYAGI, KOUICHI;KATOH, SUSUMU;SHINKAI, HISASHI;MOTOMURA, TAKAHISA;KOMODA, YASUMASA;OTSUBAKI, TOMOKO;SOEJIMA, YUKI;KAWAHARA, IICHIRO |
发明人 |
UENO, HIROSHI;SHIMADA, TAKASHI;AOYAGI, KOUICHI;KATOH, SUSUMU;SHINKAI, HISASHI;MOTOMURA, TAKAHISA;KOMODA, YASUMASA;OTSUBAKI, TOMOKO;SOEJIMA, YUKI;KAWAHARA, IICHIRO |